Last reviewed · How we verify
MW151
At a glance
| Generic name | MW151 |
|---|---|
| Also known as | MW01-2-151SRM |
| Sponsor | ImmunoChem Therapeutics, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases (PHASE1)
- MW151-101: First-in-human Study of MW151 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MW151 CI brief — competitive landscape report
- MW151 updates RSS · CI watch RSS
- ImmunoChem Therapeutics, LLC portfolio CI